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Increased chemosensitivity to hypoxia and hypercapnia, together with a prolonged circu-
latory time, are the main determinants of Cheyne-Stokes (C-S) respiration in heart failure.
To evaluate the effect of acetazolamide, a carbonic anhydrase inhibitor, on chemosensitiv-
ity and respiratory dynamics in patients with heart failure with C-S respiration, 12 patients
(mean age 62  9 years, mean left ventricular ejection fraction 24  9%) and C-S
respiration (mean apnea-hypopnea index 23  13) who underwent 4 consecutive days of
oral acetazolamide treatment (250 mg twice daily) were enrolled in this study. Assessment
of chemosensitivity to hypoxia and hypercapnia, cardiopulmonary stress testing, 24-hour
cardiorespiratory polygraphy, and neurohormonal characterization were performed at
baseline and at the end of treatment. Acetazolamide improved central apneas (apnea-
hypopnea index 23  13 to 15  9, p  0.012) and the percentage of time spent below an
arterial oxyhemoglobin saturation of 90% (16  23% to 10  18%, p  0.005). Chemo-
sensitivity to hypoxia was blunted (1.03  0.69 to 0.78  0.55 L/min/mm Hg, p  0.032),
while chemosensitivity to hypercapnia increased after acetazolamide (1.27  0.71 to
1.54  0.78 L/min/% arterial oxygen saturation, p  0.023); patients achieved a lower
workload (90  30 to 81  30 W, p <0.001), with no differences in peak oxygen
consumption, while there was an increment in the regression slope relating minute venti-
lation to carbon dioxide output (39  10 to 43  9, p  0.010). In conclusion, in patients
with heart failure, acetazolamide diminishes C-S respiration and improves oxyhemoglobin
saturation, likely by decreasing chemosensitivity to hypoxia. However, it is associated with
reduced maximal workload achieved during effort and increased chemosensitivity to
hypercapnia, inducing a reduction in the ventilatory efficiency. © 2011 Elsevier Inc. All
rights reserved. (Am J Cardiol 2011;107:1675–1680)
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eSome studies have reported a beneficial effect of acet-
azolamide, a carbonic anhydrase inhibitor, in the treatment
of central sleep apnea at high altitude1,2 and in idiopathic
entral sleep apnea.3,4 However, only 1 study has demon-
trated acetazolamide to be effective also in patients with
eart failure (HF) with Cheyne-Stokes (C-S) respiration,5
although the exact mechanisms through which this occurred
remain unclear. Increased chemosensitivity to hypercapnia6
and hypoxia7 contributes to trigger the onset and perpetuate
C-S respiration in patients with chronic HF.8,9 Furthermore,
hemosensitivity is thought to exert a direct and indepen-
ent action on the adrenergic drive,10,11 leading to ventric-
ular arrhythmias,6,8,11,12 ventilatory inefficiency during ex-
rcise,11,13 and, most important, overall worse prognosis.14
Studies in healthy subjects suggest that acetazolamide may
directly affect chemosensitivity, increasing sensitivity to
hypercapnia and decreasing sensitivity to hypoxia.15–18 We
ypothesized that acetazolamide may affect chemosensitiv-
ty to hypoxia and hypercapnia in patients with HF, a hy-
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doi:10.1016/j.amjcard.2011.01.060othesis that has never been investigated in this setting, this
eing 1 possible mechanism for its efficacy in reducing the
ncidence of C-S respiration. We therefore evaluated the
ffect of acetazolamide on chemosensitivity to hypoxia and
ypercapnia, as well as its effect on respiratory pattern at
est and during exercise.
ethods
From September 2008 to February 2010, we screened 48
mbulatory patients with HF from our clinic with left ven-
ricular systolic dysfunction (left ventricular ejection frac-
ion 50%) and C-S respiration on ambulatory cardiorespi-
atory polygraphy (apnea-hypopnea index, defined as the
umber of apnea or hypopnea episodes per hour of record-
ng,15 per hour). Exclusion criteria were New York Heart
ssociation class IV, acute coronary syndromes within the
revious 6 months, glomerular filtration rate 30 ml/min,
ulmonary disease defined as vital capacity and total lung
apacity 50% of predicted value, forced expiratory vol-
me in 1 second 50% of predicted value, and forced vital
apacity 70%. Patients with obstructive sleep apnea syn-
rome, defined as a number of obstructive events 50% of
otal hypopnea episodes, and current treatment with mor-
hine or derivatives, theophylline, oxygen, benzodiaz-
pines, or acetazolamide were also excluded. Twelve pa-
ients matched the entry criteria and were enrolled in the
www.ajconline.org
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1676 The American Journal of Cardiology (www.ajconline.org)study. In addition to the standard therapeutic regimen, pa-
tients were treated with oral acetazolamide 250 mg twice
daily for 4 days. A 4-day treatment regimen was chosen to
assess the “long-term” effect of acetazolamide administra-
tion, while the double administration was chosen to study
the effect of the drug on both nighttime and daytime C-S
respiration.
At baseline and at the end of treatment, all patients
underwent (1) evaluation of chemosensitivity; (2) blood
sampling for N-terminal–pro-brain natriuretic peptide, epi-
nephrine, norepinephrine, plasma renin activity, and aldo-
sterone; (3) arterial blood gas analysis; (4) cardiopulmonary
exercise stress testing; and (5) 24-hour ambulatory cardio-
respiratory polygraphy.
The protocol was approved by the local ethics commit-
tee. Informed consent was obtained from all subjects.
Chemosensitivity was assessed using the rebreathing
technique, as previously described.11,13 Chemosensitivity to
ypoxia, or hypoxic ventilatory response (HVR), was cal-
ulated as the linear regression slope between minute ven-
ilation and arterial oxygen saturation during the hypoxic-
ormocapnic trial. Chemosensitivity to hypercapnia, or
Figure 1. Results of rebreathing tests during hypoxic normocapnic trial
breath-by-breath ventilation are shown before (open circles) and after (so
Figure 2. Individual changes in chemosensitivity during hypoxic normoca
amide administration. Each subject is represented by a black square. Soliypercapnic ventilatory response (HCVR), was calculated ps the linear regression slope between minute ventilation
nd end-tidal carbon dioxide during the hypercapnic-
ormoxic trial. As cut-off values for defining increased
hemosensitivity, we considered 0.77 L/min/mm Hg for
VR and 0.79 L/min/% arterial oxygen saturation for
CVR (i.e., 2 times the standard deviation over the mean
alue of a control group of healthy subjects).11 All patients
ere familiar with chemosensitivity testing.
Neurohormonal assays were performed as described
lsewhere.19 Symptom-limited cardiopulmonary exercise
ests were conducted on a bicycle ergometer according to a
amp protocol (Vmax; Sensormedics, Milan, Italy). Circula-
tory power was calculated as peak oxygen uptake (VO2)
ultiplied by peak systolic blood pressure,20 and peak ox-
ygen pulse was calculated as peak VO2 divided by heart rate.
ll cardiopulmonary exercise tests were performed by the
ame physician, blinded to the results of the chemosensi-
ivity tests. All patients were familiar with cardiopulmonary
xercise testing. All subjects underwent a 24-hour continu-
us ambulatory polygraphic recording that included tho-
acic and abdominal respiratory inductance plethysmogra-
hy, airflow (using a nasal-oral thermocouple and nasal
hypercapnic-normoxic trial (b) in a representative subject. Changes in
les) acetazolamide administration.
al (left) and hypercapnic-normoxic trial (right) before and after acetazol-
circles represent the average values before and after treatment.(a) andpnic triressure recording), finger pulse oximetry, and electrocar-
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1677Heart Failure/Acetazolamide and Chemoreflexdiography (Somte; Compumedics, Abbotsford, Australia).
An episode of apnea was defined as the cessation of respi-
ratory flow for10 seconds, whereas hypopnea was defined
as a reduction in respiratory flow lasting 10 seconds and
associated with a 4% decrease in arterial oxyhemoglobin
saturation.21 Apnea and hypopnea were considered as cen-
ral or obstructive according to the combined analysis of
ibcage and abdominal excursions and airflow signal.
Statistical analysis was performed using SPSS version
3.0 (SPSS, Inc., Chicago, Illinois). Data are expressed as
ean  SD if normally distributed or as median (interquar-
ile range) otherwise. Neurohormones were logarithmically
ransformed to normalize a skewed distribution when
eeded. Paired Student’s t tests or McNemar’s tests were
erformed to compare the effect of acetazolamide with
aseline status within subjects. The sample size was deter-
ined for the principal question, namely, changes in
hemoreflex sensitivity after acetazolamide administration.
n a pilot study with 3 patients, we found that 12 patients
ould be sufficient to reach 80% power to detect changes in
CVR and HVR. A p value 0.05 was considered statis-
ically significant.
esults
The study population consisted of 12 patients with HF
11 men) receiving optimal medical therapy. The mean age
as 62 9 years, the mean body mass index 29 4 kg/m2,
nd the mean left ventricular ejection fraction 24  9%. On
he whole, patients showed at baseline a moderate degree of
eurohormonal activation: median N-terminal–pro-brain
atriuretic peptide was 1,216 ng/L (interquartile range 863
o 1,844), median norepinephrine 509 ng/L (interquartile
ange 461 to 736), median plasma renin activity 2.49 ng/L/
our (interquartile range 1.71 to 4.03), and median aldoste-
one 264 ng/L (interquartile range 122 to 279).
At baseline, 8 patients demonstrated elevated chemosen-
itivity with increases in HVR and HCVR, 1 patient dem-
nstrated an increase solely in HVR, and 3 patients had
Figure 3. Changes in the 24-hour, diurnal, and nocturnal apnea-hypop-
nea index (AHI) are shown before (black) and after (white) acetazol-
amide administration. *p 0.001 and †p 0.05, acetazolamide com-
pared to baseline.normal HVR and HCVR.Ta
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1678 The American Journal of Cardiology (www.ajconline.org)Administration of acetazolamide had different effects on
chemosensitivity to hypoxia or hypercapnia (Figures 1 and
). Indeed, while chemosensitivity to hypoxia was blunted
y acetazolamide by 24% (HVR 1.03 0.69 to 0.78 0.55
/min/mm Hg, p  0.03; Figure 2), chemosensitivity to
ypercapnia increased by 21% (HCVR 1.27  0.71 to 1.54
0.78 L/min/% arterial oxygen saturation, p  0.02; Fig-
re 2). With respect to arterial blood gas analysis, acetazol-
mide resulted in a mild metabolic acidosis, with a nonsig-
ificant trend toward a reduction of the partial arterial
ressure of carbon dioxide and a significant improvement in
he partial arterial pressure of oxygen and oxyhemoglobin
aturation (Table 1).
All patients had central sleep apnea, but 3 patients also
ad from obstructive events (relative percentage of obstruc-
ive events 43%, 22%, and 2%). Acetazolamide 250 mg
wice daily significantly reduced central sleep apnea (Table
). This stabilization of ventilation with acetazolamide was
ot confined solely to central sleep apnea at night; there was
lso a significant reduction in daytime C-S respiration, with
41% reduction of diurnal apnea-hypopnea index (Figure
). The observed improvement in apnea-hypopnea index
as due to a reduction in central events, because there was
o decrease in the number of obstructive events in the 3
atients with episodes of obstructive sleep apnea. The re-
uction in central events was associated with a significant
mprovement in arterial oxyhemoglobin saturation, as re-
ected by a 36% decrease of the total time spent with a
aturation 90% (Table 1) and by an increase in the min-
mal oxygen saturation achieved during apneas (82  5 to
6  3, p  0.001).
At baseline, the main limitation to exercise was dyspnea,
s reported by 9 patients, whereas after acetazolamide ad-
inistration, leg fatigue became the predominant limiting
ymptom, which was reported by 9 patients. Exertional
scillatory ventilation was demonstrated in 6 of 12 patients;
ts prevalence was unchanged by 4 days of treatment with
cetazolamide. Exercise capacity after acetazolamide ad-
inistration was reduced by 10%, with no change in peak
O2 reached. Acetazolamide was associated with a 13%
increase in the regression slope relating ventilation to car-
bon dioxide production (minute ventilation/carbon dioxide
production slope), despite no difference in peak ventilation
(Table 2). Maximal heart rate and blood pressure were
lower at peak exercise on acetazolamide, with a correspond-
ing significant reduction in the rate-pressure product (all
p values 0.05), while there was no difference in the
circulatory power and in the peak oxygen pulse (data not
shown).
Despite an increase in hypercapnic chemosensitivity af-
ter acetazolamide, there was no clear change in sympathetic
activation, heart rate at rest, systolic and diastolic blood
pressure, and plasma norepinephrine, N-terminal–pro-brain
natriuretic peptide, plasma renin activity, and aldosterone
concentration (data not shown).
Discussion
This study demonstrates that in patients with HF and C-S
respiration, acetazolamide blunts chemosensitivity to hyp-
oxia while increasing the chemosensitivity to hypercapnia.Ta
b
Ca
r
Pa
t 1 2 3 4 5 6 7 8 9 10 11 12 M
e
p
v V
e
t
t
a
c
H
a
o
e
p
r
b
i
t
v
p
h
i
m
s
t
h
r
H
a
r
a
m
d
p
a
d
e
a
d
d
l
a
a
a
c
v
i
r
c
i
v
t
s
m
n
b
c
g
m
t
c
w
a
j
c
a
e
a
p
o
b
a
s
1679Heart Failure/Acetazolamide and ChemoreflexThis action on the chemoreflex is associated with (1) sig-
nificant decreases in nighttime and daytime C-S respiration
and (2) improvement in oxygen saturation, with no adverse
impact on sympathetic activation. However, acetazolamide
was associated with a negative effect on maximal workload
achieved during exercise and on ventilatory efficiency, with
no change in peak VO2.
The effectiveness of acetazolamide on central sleep ap-
nea in patients with HF has previously been demonstrated5;
however, the present study extends this finding to daytime
periodic breathing and proposes a mechanism of action. The
half-life of acetazolamide means that, when administered
twice a day, its effects can be demonstrated over a full
24-hour period, unlike other treatment strategies, such as
noninvasive mechanical ventilation or supplemental over-
night oxygen therapy.
Experimental evidence on dogs22 has suggested that ac-
tazolamide might exert its positive action on C-S respira-
ion by increasing the gap between the apneic threshold and
he prevailing carbon dioxide. However, a direct effect of
cetazolamide on chemoreflex sensitivity, which plays a
ritical role in the onset of C-S respiration in patients with
F,6–8 may also contribute the beneficial actions of acet-
zolamide. The blunting effect on chemosensitivity to hyp-
xia and the stimulation of chemosensitivity to hypercapnia
licited by acetazolamide, demonstrated for the first time in
atients with HF in our study, is consistent with previous
eports in healthy subjects.15–18 Central chemosensitivity is
elieved to be responsible for ventilation and carbon diox-
de set-point determination, while peripheral chemosensi-
ivity to oxygen and carbon dioxide favors the fluctuation of
entilation and respiratory gases around their mean set
oints.8 Indeed, the blunting effects of acetazolamide on the
ypoxic ventilatory response could be responsible for the
mprovement of periodic breathing observed after drug ad-
inistration. Moreover, the improvement in oxyhemoglobin
aturation (after the reduction in diurnal and nocturnal cen-
ral apnea) could further limit the hypoxic stimulus for
yperventilation and positively modulate the carbon dioxide
esponse of the peripheral chemoreceptors,23 favoring the
development of a virtuous cycle that stabilizes periodic
breathing.
There is growing evidence that the enhancement of che-
mosensitivity to hypercapnia, a powerful and independent
predictor of mortality in patients with HF, may play an
unfavorable role in HF progression through an increase in
sympathetic drive,10 eliciting autonomic imbalance, neuro-
hormonal activation, abnormal ventilatory responses, and
ventricular arrhythmias.11,14 The observation of increased
CVR and of a neutral effect on neurohormonal activation
fter treatment with acetazolamide raises some concerns
egarding potential negative effects of long-term acetazol-
mide administration.
We found a 10% reduction in workload achieved at
aximal exercise level, with leg fatigue becoming the pre-
ominant limiting symptom. This is in accordance with
revious reports in healthy subjects18 and may be due to
cetazolamide-induced mild acidosis that may decrease en-
urance time, through the inhibition of glycolytic enzymes,
specially phosphofructokinase.24 Interestingly, whateverthe mechanism of the reduction in individual workload, nodifference in peak VO2 achieved at maximal exercise was
seen. Moreover, the VO2/work slope was higher after acet-
zolamide treatment, counterbalancing the effect of the re-
uced workload achieved on peak VO2. This effect could be
ue to the improvement in oxyhemoglobin saturation re-
ated to the disappearance or attenuation of C-S respiration
nd to a plausible right shift in the oxyhemoglobin dissoci-
tion curve due to acidosis (Bohr effect).
As far as respiratory dynamics is concerned, ventilation
t rest was unchanged, while peak exercise ventilation in-
reased on acetazolamide compared to baseline. The similar
entilation at rest could be related to the balance between an
nhibitory effect of acetazolamide on the peripheral chemo-
eceptor and the stimulant effect on the central chemore-
eptor. In contrast, the observed increased ventilation dur-
ng exercise, associated with an increase in the minute
entilation/carbon dioxide production slope, may be related
o the stimulating action of acetazolamide on the chemo-
ensitivity to hypercapnia.
Finally, the net balance of acetazolamide (decreased che-
osensitivity to hypoxia/increased sensitivity to hypercap-
ia) on sympathetic drive appears to be neutral, as indicated
y the absence of significant changes in rest norepinephrine
oncentration before versus after treatment.
A major limitation of this study was the lack of a control
roup. However, all patients were familiar with cardiopul-
onary exercise testing and the chemosensitivity evalua-
ion, limiting intrapatient variability, and the individual
hanges observed in chemoreflex sensitivity after treatment
ere consistent in all patients, as shown in Figure 2, and in
ccordance with previous studies conducted in healthy sub-
ects. Second, this was a short-term study, and studies spe-
ifically focused on long-term response to chronic acetazol-
mide administration are needed to highlight the long-term
ffects of acetazolamide on acid-base balance, sympathetic
ctivation, exercise capacity and chemosensitivity. Third,
lasma norepinephrine assay is only an approximate marker
f sympathetic drive, but plasma norepinephrine level can
e used for a rough estimation of the degree of sympathetic
ctivation and has been proved to change in response to
timuli and drugs known to act on the sympathetic drive.
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